Oxacillin: Pediatric drug information

For additional information see "Oxacillin: Drug information" and "Oxacillin: Patient drug information"

For abbreviations, symbols, and age group definitions show table

Therapeutic Category

Antibiotic, Penicillin (Antistaphylococcal)

Dosing: Neonatal

General dosing (nonmeningitis):

Age-directed dosing (Ref): IV, IM:

Gestational Age	Postnatal Age	Dose
≤34 weeks	≤7 days	25 mg/kg/dose every 12 hours
≤34 weeks	8 to 28 days	25 mg/kg/dose every 8 hours
>34 weeks	≤7 days	25 mg/kg/dose every 8 hours
>34 weeks	8 to 28 days	25 mg/kg/dose every 6 hours

Weight-directed dosing (Ref): IV, IM:

Body Weight	Postnatal Age	Dose
<1 kg	≤14 days	25 mg/kg/dose every 12 hours
	15 to 28 days	25 mg/kg/dose every 8 hours
	29 to 60 days	37.5 mg/kg/dose every 6 hours
1 to 2 kg	≤7 days	25 mg/kg/dose every 12 hours
	8 to 28 days	25 mg/kg/dose every 8 hours
	29 to 60 days	37.5 mg/kg/dose every 6 hours
>2 kg	≤7 days	25 mg/kg/dose every 8 hours
	8 to 28 days	25 mg/kg/dose every 6 hours
	29 to 60 days	37.5 mg/kg/dose every 6 hours

Meningitis

Meningitis (Ref): IV, IM:

Body Weight	Postnatal Age	Dose
<1 kg	≤14 days	50 mg/kg/dose every 12 hours
	15 to 28 days	50 mg/kg/dose every 8 hours
	29 to 60 days	75 mg/kg/dose every 6 hours
1 to 2 kg	≤7 days	50 mg/kg/dose every 12 hours
	8 to 28 days	50 mg/kg/dose every 8 hours
	29 to 60 days	75 mg/kg/dose every 6 hours
>2 kg	≤7 days	50 mg/kg/dose every 8 hours
	8 to 28 days	50 mg/kg/dose every 6 hours
	29 to 60 days	75 mg/kg/dose every 6 hours

Dosing: Pediatric

General dosing: Infants, Children, and Adolescents: IV, IM: 100 to 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 g/day (Ref).

Endocarditis, treatment

Endocarditis, treatment: Children and Adolescents: IV: 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 g/day. Treat for at least 4 to 6 weeks; duration should be individualized based on presentation, valve type, and response to therapy (Ref).

Meningitis/Ventriculitis

Meningitis/Ventriculitis: Infants, Children, and Adolescents: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 g/day (Ref).

Osteoarticular infection, acute

Osteoarticular infection, acute (eg, septic arthritis, osteomyelitis): Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/day divided every 4 to 6 hours; maximum daily dose: 12 g/day (Ref). May transition to oral therapy as appropriate (eg, response to initial parenteral therapy, oral option available). Minimum total duration is 2 to 3 weeks for septic arthritis and 3 to 4 weeks for osteomyelitis; however, duration should be individualized based on several factors, including causative pathogen, response to therapy, and normalization of inflammatory markers (Ref).

Pneumonia, community-acquired moderate to severe infection, methicillin-susceptible Staphylococcus aureus

Pneumonia, community-acquired (CAP) moderate to severe infection, methicillin-susceptible Staphylococcus aureus (MSSA):

Infants >3 months, Children, and Adolescents: IV: 150 to 200 mg/kg/day divided every 6 to 8 hours (Ref).

Skin and soft tissue infection

Skin and soft tissue infection (Ref):

Infants, Children, and Adolescents:

MSSA (non-necrotizing infection): IV: 100 to 150 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 g/day.

Necrotizing infection due to MSSA: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 g/day; continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Altered kidney function:

Infants, Children, and Adolescents: IV, IM: There are no dosage adjustments provided in the manufacturer's labeling; however, oxacillin is eliminated via the kidney; monitoring is recommended. High oxacillin concentrations and neurotoxicity have been reported in adult patients with severe kidney impairment; monitor closely (Ref).

Hemodialysis: Not significantly dialyzed (Ref):

Infants, Children, and Adolescents: IV, IM: No specific dosage adjustment recommended; however, high oxacillin concentrations and neurotoxicity have been reported in adult patients with severe kidney impairment; monitor closely (Ref).

Peritoneal dialysis: Minimally dialyzed (5%) (Ref):

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Adult

(For additional information see "Oxacillin: Drug information")

Usual dosage range: IV: 1 to 2 g every 4 to 6 hours; may also administer total daily dose as a continuous infusion over 24 hours (eg, for a dose of 2 g every 4 hours, administer 12 g over 24 hours) (Ref).

Bloodstream infection

Bloodstream infection: Pathogen-directed therapy for methicillin-susceptible staphylococci (off label): IV: 2 g every 4 hours; treat uncomplicated bacteremia for ≥14 days starting from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (Ref)

Endocarditis, treatment

Endocarditis, treatment: Pathogen-directed therapy for methicillin-susceptible staphylococci (off label):

Native valve: IV: 12 g/day in 4 or 6 divided doses (ie, 2 g every 4 hours or 3 g every 6 hours) for 6 weeks. For uncomplicated right-sided ineffective endocarditis, 2 weeks of therapy may be adequate (Ref)

Prosthetic valve: IV: 12 g/day in 6 divided doses (ie, 2 g every 4 hours) for ≥6 weeks; use with rifampin for entire duration of therapy and gentamicin for first 2 weeks (Ref).

Meningitis, bacterial

Meningitis, bacterial: Pathogen-directed therapy for methicillin-susceptible staphylococci (off label): IV: 2 g every 4 hours; consider addition of rifampin if organism is susceptible and prosthetic material is present. Treatment duration is 10 to 14 days, depending on causative pathogen(s) and clinical response (Ref).

Osteomyelitis and/or discitis

Osteomyelitis and/or discitis: Pathogen-directed therapy for methicillin-susceptible staphylococci (off label): IV: 1.5 to 2 g every 4 to 6 hours or via continuous infusion for ≥6 weeks depending on extent of infection, debridement, and clinical response (Ref).

Pneumonia

Pneumonia: Pathogen-directed therapy for methicillin-susceptible S. aureus (off label): IV: 2 g every 4 hours (Ref). Minimum duration is generally 5 days for community-acquired pneumonia and 7 days for hospital-acquired or ventilator-associated pneumonia; patients should be clinically stable with normal vital signs before therapy is discontinued (Ref).

Prosthetic joint infection

Prosthetic joint infection: Pathogen-directed therapy for methicillin-susceptible staphylococci (off label): IV: 1.5 to 2 g every 4 to 6 hours; duration ranges from 2 to 6 weeks depending on prosthesis management, use of rifampin, and other patient-specific factors (Ref).

Skin and soft tissue infection

Skin and soft tissue infection:

Cellulitis (nonpurulent) in patients without risk for methicillin-resistant S. aureus: IV: 1 to 2 g every 4 hours. Total duration of therapy is ≥5 days (including oral step-down therapy); may extend up to 14 days depending on severity and clinical response (Ref).

Necrotizing infection due to methicillin-susceptible S. aureus (MSSA) (off label): IV: 1 to 2 g every 4 hours; continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (Ref).

Surgical site incisional infection (trunk or extremity, not involving axilla or perineum) (off label): IV: 2 g every 6 hours; duration is dependent upon severity, need for debridement, and clinical response (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

CrCl ≥10 mL/minute: No dosage adjustment necessary (Ref).

CrCl <10 mL/minute: No specific dosage adjustment recommended; however, monitor closely as high oxacillin concentrations and neurotoxicity have been reported in this population (Ref). When treating less severe infections, a maximum daily dose of 8 g/day may be considered (Ref).

Intermittent hemodialysis (thrice weekly): Not significantly dialyzed (Ref): No specific dosage adjustment recommended; however, monitor closely as high oxacillin concentrations and neurotoxicity have been reported in this population (Ref). When treating less severe infections, a maximum daily dose of 8 g/day may be considered (Ref).

Peritoneal dialysis: Minimally dialyzed (5%) (Ref): No specific dosage adjustment recommended; however, monitor closely as high oxacillin concentrations and neurotoxicity have been reported in this population (Ref). When treating less severe infections, a maximum daily dose of 8 g/day may be considered (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified.

Postmarketing:

Gastrointestinal: Clostridioides difficile-associated diarrhea, clostridioides difficile colitis (Thomas 1984)

Hematologic: Agranulocytosis, bone marrow depression, granulocytopenia (Brook 1977), leukopenia (Brook 1977), neutropenia (Passoff 1978)

Hepatic: Hepatitis (Al-Homaidhi 2002), hepatotoxicity, increased serum aspartate aminotransferase

Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Sharpe 2019)

Renal: Acute renal tubular disease, interstitial nephritis

Contraindications

Hypersensitivity (eg, anaphylaxis) to oxacillin, any penicillin, or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Anaphylactic/hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in patients with histories of significant allergies and/or asthma; discontinue treatment and institute appropriate therapy if an allergic reaction occurs

• Hepatitis: Acute hepatitis and reversible elevations of serum transaminases have been reported sometimes accompanied by rash and leukopenia; onset after 2 to 3 weeks of therapy (Dahlgren 1997; Faden 2009; Maraqa 2002).

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Renal impairment: Use with caution in severe impairment.

Special populations:

• Older adult: May contain a significant amount of sodium; consult product specific labeling for amount. Older adults may respond with a blunted natriuresis to salt loading. This may be clinically important in diseases such as congestive heart failure.

Warnings: Additional Pediatric Considerations

Hepatotoxicity and rash are more common with oxacillin compared to other parenteral antibiotics; in a study of pediatric patients (5 to 19 years) receiving outpatient parenteral antimicrobial therapy (oxacillin n=41; nafcillin n=58; "other" antibiotics n=146), significantly more hepatotoxicity (22%) and rash (31.7%) were reported in the oxacillin group compared to the nafcillin group (0% and 10.3%) or other antibiotics (1.4% and 1.4%) (Maraqa 2002).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Generic: 1 g/50 mL (50 mL); 2 g/50 mL (50 mL)

Solution Reconstituted, Injection:

Generic: 1 g (1 ea); 2 g (1 ea)

Solution Reconstituted, Injection [preservative free]:

Generic: 1 g (1 ea); 2 g (1 ea)

Solution Reconstituted, Intravenous:

Generic: 10 g (1 ea)

Solution Reconstituted, Intravenous [preservative free]:

Generic: 10 g (1 ea)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Oxacillin Sodium in Dextrose Intravenous)

1 gm/50 mL (per mL): $0.41

2 gm/50 mL (per mL): $0.59

Solution (reconstituted) (Oxacillin Sodium Injection)

1 g (per each): $13.50 - $14.50

2 g (per each): $10.80 - $29.00

Solution (reconstituted) (Oxacillin Sodium Intravenous)

10 g (per each): $66.30 - $145.00

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Additional Information

May contain a significant amount of sodium; consult product specific labeling for amount.

Administration: Pediatric

Parenteral:

IM: Administer by deep IM injection into a large muscle mass (eg, gluteus maximus); avoid sciatic nerve injury.

IV:

Direct IV injection: Administer over 10 minutes at a concentration of 100 mg/mL.

Intermittent IV infusion: Administer over 15 to 30 minutes (Ref); extending the infusion over 60 minutes has been used for peripheral administration by some ambulatory centers to decrease the risk of phlebitis in home care patients (Ref).

Administration: Adult

IV: Administer IVP over 10 minutes or IVPB over 30 minutes. Total daily dose may also be administered over 24 hours as a continuous infusion (Ref).

Storage/Stability

Premixed infusions: Store in a freezer at -20°C (-4°F). Thaw at room temperature or under refrigeration only. Thawed bags are stable for 21 days under refrigeration or 48 hours at room temperature. Do not refreeze.

Vials: Store intact vials at 20°C to 25°C (68°F to 77°F); refer to manufacturer's labeling for specific storage instructions after dilution (varies by concentration and diluent).

Use

Treatment of infections due to susceptible penicillinase-producing staphylococci (FDA approved in all ages).

Metabolism/Transport Effects

Substrate of OAT1/3

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Acemetacin: May increase the serum concentration of Penicillins. Risk C: Monitor therapy

Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. Risk C: Monitor therapy

Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. Risk C: Monitor therapy

Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Methotrexate: Penicillins may increase the serum concentration of Methotrexate. Risk C: Monitor therapy

Mycophenolate: Antibiotics may decrease serum concentrations of the active metabolite(s) of Mycophenolate. Specifically, concentrations of mycophenolic acid (MPA) may be reduced. Risk C: Monitor therapy

Probenecid: May increase the serum concentration of Penicillins. Risk C: Monitor therapy

Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Tetracyclines: May diminish the therapeutic effect of Penicillins. Risk C: Monitor therapy

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Dietary Considerations

Some products may contain sodium.

Pregnancy Considerations

Oxacillin crosses the placenta.

Although it is highly protein bound, therapeutic concentrations can be found in the amniotic fluid following IV administration (Nau 1987).

As a class, penicillin antibiotics are widely used in pregnant women. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Czeizel 1999; Damkier 2019; Lamont 2014; Muanda 2017a; Muanda 2017b).

Monitoring Parameters

CBC with differential, urinalysis, BUN, serum creatinine, AST and ALT; number and type of stools/day for diarrhea; observe IV site for extravasation.

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Into bile, pleural fluids; insignificant concentrations in CSF and aqueous humor.

Protein binding: ~94% (mainly albumin).

Metabolism: Hepatic.

Half-life elimination:

Preterm neonates (PNA: 8 to 15 days): 96 minutes (Axline 1967).

Term neonates >1 week of age, Infants, and Children ≤2 years: 78 minutes; range: 53 to 109 minutes (Burckhart 1978).

Adults: 20 to 30 minutes; prolonged with renal impairment.

Time to peak, serum: IM: 30 minutes; IV: 5 minutes.

Excretion: Urine and bile (unchanged drug).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Anti-infective considerations:

Parameters associated with efficacy: Time dependent, associated with time free drug concentration (fT) > minimum inhibitory concentration (MIC); goal: ≥50% fT > MIC (bactericidal) (Drusano 2003; Turnidge 1998).

Critically ill patients in the ICU: Minimum goal: ≥50% fT > MIC; preferred goal: ≥100% fT > MIC (Abdul-Aziz 2020; Al-Shaer 2020; Roberts 2014); some experts favor ≥100% fT > 4 times the MIC (Guilhaumou 2019).

Expected drug exposure:

C_max(peak): Single dose: IV: Adults: 500 mg: 43 mg/L.

Postantibiotic effect: Minimal bacterial killing continues after concentration of penicillins fall below the MIC of targeted pathogen and varies based on the organism:

Gram-positive cocci: 1.5 to 3.5 hours (Craig 1991).

Gram-negative bacilli: 0 to 1.5 hours (Craig 1991).

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Prostaphlin;
(BE) Belgium: Penstapho;
(BF) Burkina Faso: Bristopen;
(BG) Bulgaria: Oxacilin;
(BR) Brazil: Bactocilin | Oxacilil | Oxacilina | Oxacilina sodica | Oxanon | Oxapen | Prodoxacilina | Staficilin n | Teutocilin;
(CI) Côte d'Ivoire: Oxacare;
(CN) China: Oxacillin;
(CO) Colombia: Oxacidelt | Oxacil | Oxacilina | Prostafilina;
(CZ) Czech Republic: Oxacilin | Oxacilin avmc | Oxacilina atb | Prostaphlin;
(DE) Germany: Infectostaph;
(DO) Dominican Republic: Prostafilina;
(EC) Ecuador: Oxacilina;
(EE) Estonia: Oxacilina Antibiotice | Oxacillin | Oxacillin natrium | Prostaphlin;
(FR) France: Bristopen | Istopen | Oxacilline Panpharma;
(HU) Hungary: Prostaphlin;
(JP) Japan: Prostaphlin | Staphcillin v;
(LT) Lithuania: Oxacilin | Oxacillin | Oxacillin natrium | Oxin | Pan oxacillin | Prostaphlin;
(LU) Luxembourg: Penstapho;
(LV) Latvia: Oxacilin | Oxacilina | Oxacillin | Oxacillin natrium | Oxin | Prostaphlin;
(MA) Morocco: Bristopen;
(PE) Peru: Dicloxal ox | Oxacilina | Oxalin;
(PH) Philippines: Bactocill | Cilvex | Oxal | Oxan | Oxapen | Oxatalis | Panadox | Peoxa | Pharmawealth oxacillin | Prostaphlin | Stafcil | Wydox | Yss oxacillin sodium;
(PL) Poland: Oxacilin;
(PR) Puerto Rico: Oxacillin;
(PY) Paraguay: Oxacilin lasca | Oxacilina dutriec | Oxacilina nortelab | Oxameg;
(RO) Romania: Oxacilina atb | Oxacillin Atb;
(RU) Russian Federation: Oxacillin | Prostaphlin;
(SA) Saudi Arabia: Prostaphlin;
(SK) Slovakia: Oxacilin | Prostaphlin;
(TH) Thailand: Prostaphlin;
(TN) Tunisia: Bristopen | Oxacil | Staphymicine;
(TW) Taiwan: Ocillina | Oxacillin | Prostaphlin;
(UA) Ukraine: Oxacillin | Oxacillin natrium;
(UY) Uruguay: Oxacilina;
(VE) Venezuela, Bolivarian Republic of: Biocilina | Oxacilina | Oxawell | Oxiclin | Oxipen | Prostafilina

Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/Pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1 [PubMed 32383061]
Ailes EC, Gilboa SM, Gill SK, et al; the National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. Birth Defects Res A Clin Mol Teratol. 2016;106(11):940-949. doi:10.1002/bdra.23570 [PubMed 27891788]
Al-Homaidhi H, Abdel-Haq NM, El-Baba M, Asmar BI. Severe hepatitis associated with oxacillin therapy. South Med J. 2002;95(6):650-652. [PubMed 12081223]
Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients. J Antimicrob Chemother. 2020;75(12):3644-3651. doi:10.1093/jac/dkaa359 [PubMed 32910809]
American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
Axline SG, Yaffe SJ, Simon HJ. Clinical pharmacology of antimicrobials in premature infants. II. Ampicillin, methicillin, oxacillin, neomycin, and colistin. Pediatrics. 1967;39(1):97-107. [PubMed 6016648]
Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296 [PubMed 26373316]
Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. Circulation. 2015;132(15):1487-1515. [PubMed 26373317]
Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61(6):e26-e46. [PubMed 26229122]
Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. Pharmacotherapy. 2015;35(11):1052-1062. doi:10.1002/phar.1649 [PubMed 26598097]
Bradley JS, Byington CL, Shah SS, et al. “The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America”, Clin Infect Dis, 2011, 53(7):e25-76. [PubMed 21880587]
Bradley JS, Nelson JD, Kimberlin DK, et al, eds. Nelson's Pocket Book of Pediatric Antimicrobial Therapy. 28th ed. American Academy of Pediatrics; 2022.
Brook I. Leukopenia and granulocytopenia after oxacillin therapy. South Med J. 1977;70(5):565-566. doi:10.1097/00007611-197705000-00018 [PubMed 860144]
Bulger RJ, Lindholm DD, Murray JS, Kirby WM. Effect of uremia on methicillin and oxacillin blood levels. JAMA. 1964;187:319-322. doi:10.1001/jama.1964.03060180005001 [PubMed 14085025]
Burckart GJ, Evans WE, Whitington GL. Comparison of antibiotic serum concentrations after intramuscular oxacillin and oral cloxacillin in children. Am J Hosp Pharm. 1978;35(11):1380-1382. [PubMed 707507]
Craig WA. The postantibiotic effect. Clin Microbiology Newsletter. 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y
Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188 [PubMed 19884587]
Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. Teratogenic evaluation of oxacillin. Scand J Infect Dis. 1999;31(3):311-312. doi:10.1080/00365549950163635 [PubMed 10482063]
Dahlgren A. Adverse drug reactions in home care patients receiving nafcillin or oxacillin. Am J Health-Syst Pharm. 1997;54(10):1176-1179. [PubMed 9161625]
Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050 [PubMed 31260651]
Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” N Engl J Med, 1988, 318(7):419-26 and 318(8):490-500. [PubMed 3277054]
Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36(suppl 1):S42-S50. doi:10.1086/344653 [PubMed 12516029]
Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Faden D, Faden HS. The high rate of adverse drug events in children receiving prolonged outpatient parenteral antibiotic therapy for osteomyelitis. Pediatr Inf Dis J. 2009;28(6):539-541. [PubMed 19483522]
Golightly LK, Teitelbaum I, Kiser TH, et al, eds. Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys. Springer Science; 2013.
Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). Crit Care. 2019;23(1):104. doi:10.1186/s13054-019-2378-9 [PubMed 30925922]
Hughes DW, Frei CR, Maxwell PR, et al. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(5):2014-2019. doi:10.1128/AAC.01232-08 [PubMed 19258261]
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353 [PubMed 27418577]
Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. J Pharm Technol. 1989;5(3):101-128. [PubMed 10318297]
Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 20, 2022.
Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580 [PubMed 25189188]
Maraqa NF, Gomez MM, Rathore HH, et al. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin Inf Dis. 2002;34(1):50-54. [PubMed 11731945]
Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Disease Society of America. Clin Infect Dis. 2009;49(1):1-45. [PubMed 19489710]
Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Resp Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST. [PubMed 31573350]
Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J Clin Pharmacol. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364 [PubMed 28722171]
Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020 [PubMed 28461374]
Nau H. Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. Dev Pharmacol Ther. 1987;10(3):174-198. doi:10.1159/000457744 [PubMed 3301235]
Neuville M, El-Helali N, Magalhaes E, et al. Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects. Ann Intensive Care. 2017;7(1):34. doi:10.1186/s13613-017-0255-8 [PubMed 28332157]
Olans RN and Weiner LB, “Reversible Oxacillin Hepatotoxicity,” J Pediatr, 1976, 89(5):835-8. [PubMed 978335]
Osmon DR, Berbari EF, Berendt AR, et al, “Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,” Clin Infect Dis, 2013, 56(1):e1-25. [PubMed 23223583]
Oxacillin injection 1 g, 2 g, and 10 g [prescribing information]. Lake Zurich, IL: Fresenius Kabi; June 2020.
Oxacillin injection galaxy container [prescribing information]. Deerfield, IL: Baxter Healthcare; September 2018.
Passoff TL, Sherry HS. Oxacillin induced neutropenia. A case report. Clin Orthop Relat Res. 1978;(135):69-70. [PubMed 709954]
Prigot A, Froix C, Rubin E. Absorption, distribution, and excretion of a new penicillin, oxacillin. Antimicrob Agents Chemother. 1962:402-410.
Refer to manufacturer's labeling.
Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072-1083. doi:10.1093/cid/ciu027 [PubMed 24429437]
Robinson DC, Cookson TL, and Grisafe JA, "Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients," Drug Intell Clin Pharm, 1987, 21(12):985-9. [PubMed 3428165]
Ruedy J. The effects of peritoneal dialysis on the physiological disposition of oxacillin, ampicillin and tetracycline in patients with renal disease. Can Med Assoc J. 1966;94(6):257-261. [PubMed 5903164]
Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and joint infections. Pediatr Infect Dis J. 2017;36(8):788-799. doi:10.1097/INF.0000000000001635 [PubMed 28708801]
Schuster KM, Wilson D, Schulman CI, Pizano LR, Ward CG, Namias N. Continuous-infusion oxacillin for the treatment of burn wound cellulitis. Surg Infect (Larchmt). 2009;10(1):41-45. doi:10.1089/sur.2007.081 [PubMed 19245363]
Sharpe A, Mourad BM, Hardwick CJ, et al. Oxacillin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Am J Case Rep. 2019;20:345-348. [PubMed 30877266]
Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 17, 2022.
Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296 [PubMed 24947530]
Thomas E, Mehta JB. Pseudomembranous colitis due to oxacillin therapy. South Med J. 1984;77(4):532-533. doi:10.1097/00007611-198404000-00036 [PubMed 6710214]
Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-1284. [PubMed 15494903]
Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis [published online February 14, 2017]. Clin Infect Dis. doi: 10.1093/cid/ciw861. [PubMed 28203777]
Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10-22. doi:10.1086/514622 [PubMed 9675443]
Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America (PIDS/IDSA): 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. J Pediatric Infect Dis Soc. 2021;10(8):801-844. doi:10.1093/jpids/piab027 [PubMed 34350458]
World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. https://www.who.int/maternal_child_adolescent/documents/55732/en/. Published 2002.
Wright AJ, “The Penicillins,” Mayo Clin Proc, 1999, 74(3):290-307. [PubMed 10090000]
Yoshikawa TT, “Antimicrobial Therapy for the Elderly Patient,” J Am Geriatr Soc, 1990, 38(12):1353-72. [PubMed 2254575]

Topic 12663 Version 306.0

خرید پکیج

Oxacillin: Pediatric drug information